Core Viewpoint - Genmab A/S announced plans to offer $1.5 billion of senior secured notes due 2032 and $1.0 billion of senior unsecured notes due 2033 to finance the acquisition of Merus N.V. [1][2][3] Financing Details - The company is launching a new $2.0 billion senior secured term loan "B" facility, in addition to a previously syndicated $1.0 billion senior secured term loan "A" facility and a $500 million senior secured revolving credit facility [2] - The net proceeds from the offering of the Notes, along with borrowings under the New Credit Facilities and cash on hand, will be used to fund the acquisition of Merus and related expenses [3] Security and Guarantees - Prior to the acquisition closing, the Notes will be secured by segregated securities accounts of Genmab, with the gross proceeds held therein [4] - After the acquisition, the Secured Notes will be secured by a first priority security interest in certain assets of Genmab and its subsidiaries [4] Indenture Covenants - The indentures governing the Notes are expected to include customary covenants that restrict Genmab and its subsidiaries from incurring additional debt, paying dividends, and engaging in certain transactions without exceptions [5] Regulatory Information - The Notes will not be registered under the Securities Act of 1933 and will only be available to qualified institutional buyers or non-U.S. persons outside the United States [6]

Core Viewpoint - Elis has successfully priced a €350 million issuance of senior unsecured notes under its EMTN Programme, reflecting strong investor confidence in the company's business model and future prospects [2][3]. Financial Details - The notes have a maturity of 6 years and carry a fixed annual coupon of 3.375% [2]. - The net proceeds from this issuance will primarily be used to refinance existing notes amounting to €350 million due on February 15, 2026 [3]. Market Reception - The transaction received an extremely positive reception, indicated by strong investor demand and tight pricing, showcasing confidence in the resilience of Elis's business model [3]. Strategic Context - This issuance is part of Elis's active refinancing strategy and aligns with the company's cash allocation policy announced in March 2025 [3]. Placement Information - The bond placement was facilitated by a syndicate of nine banks, including notable institutions such as HSBC and Société Générale [4]. Company Overview - Elis is recognized as a leader in circular services, operating in 31 countries and focusing on customer needs related to protection, hygiene, and well-being while supporting environmental objectives [5]. - The company utilizes a rental-maintenance model optimized by traceability technologies, contributing to its sustainable value creation for shareholders, customers, and employees [5].